Evaluation of the Efficacy of Tenofovir Alafenamide in Patients with Low-Level Viremia Under Chronic Hepatitis B Treatment

  1. Alper Tahmaz
  2. Merve Yıldız Dikmen
  3. Figen Yıldırım
  4. Türkkan Öztürk Kaygusuz
  5. Oğuz Karabay
  6. Mustafa Kemal Çelen
  7. Sevil Alkan
  8. Tuba Damar Çakırca
  9. Fethiye Akgül
  10. Sıla Akhan
  11. Esra Gürbüz
  12. Şafak Özer Balin
  13. Mehmet Çelik
  14. Mehmet Çabalak
Read the full article

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

In a multicenter, retrospective study of 62 patients, we aimed to investigate whether switching from entecavir (ETV) or tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) is a superior treatment strategy for patients with chronic hepatitis B (CHB) experiencing low-level viremia (LLV). The study found that TAF significantly improved virological and biochemical outcomes. At 48 weeks, the sustained virological response was 77.8% for those who switched from ETV and 81.8% for those who switched from TDF, with HBV DNA negativity reaching 81% by month 12. Significant normalization of liver enzymes, albumin, and platelets was also observed. While switching from TDF was associated with a significant increase in triglycerides and HDL and a decrease in eGFR, no such changes were noted in the ETV group. This evidence suggests that TAF provides better virological control, promotes the regression of liver fibrosis, and may reduce the risk of hepatocellular carcinoma (HCC), making it a more advantageous option than continuing prior monotherapy.

Article activity feed

  1. Version published to 10.20944/preprints202509.2075.v1